Wire · opportunities
Aurobindo Pharma Completes Unit-VI USFDA Inspection and Launches First US Inhalation Product
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
Aurobindo Pharma launched its first US inhalation product, a generic Advair Diskus, marking entry into the complex respiratory generics market. Its subsidiary Apitoria Pharma passed the latest USFDA inspection at Unit-VI with only minor procedural observations, supporting stable operations.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to see entering US respiratory inhalation generics as a move into a higher-margin, complex segment where competition is heating up. The minor FDA findings mean you must act quickly to avoid compliance risks that could stall your market access.
◆ Coverage
1 source · 31 Aug 2026
◆ Related on Wire
◆ Topics